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Highlights 
• FGF21 increases glucose and lipid uptake in adipose tissue. 
• The selective FGF21-induced increase in lipid uptake in BAT may fuel thermogenesis. 
• Unlike BAT, glucose uptake in WAT may be used for lipogenesis.  
 
 
Abstract 
Objective: Fibroblast growth factor 21 (FGF21) has been shown to rapidly lower body weight 
in the Siberian hamster, a preclinical model of adiposity. This induced negative energy balance 
mediated by FGF21 is associated with both a lowered caloric intake and increased energy 
expenditure. Previous work has demonstrated that adipose tissue (AT) is one of the primary 
sites of FGF21 action and may be responsible for its ability to increase whole-body metabolic 
rate. The present study sought to determine the relative importance of white [subcutaneous 
WAT (sWAT) and visceral WAT (vWAT)] and brown [interscapular brown AT (iBAT)] in 
governing the FGF21-mediated metabolic improvements using tissue specific uptake of 
glucose and lipids as a proxy for metabolic activity.  
Methods: We used positron emission tomography–computed tomography (PET-CT) imaging 
in combination with both glucose (18F-fluorodeoxyglucose) and lipid (18F-4-thiapalmitate) 
tracers to assess the effect of FGF21 on tissue specific uptake of these metabolites, and 
compare responses to a control group pair-fed to match the food intake of the FGF21-treated 
group. In vivo imaging was combined with ex vivo tissue specific functional, biochemical and 
molecular analyses of nutrient uptake and signalling pathways. 
Results: Consistent with previous findings, FGF21 reduced body weight via a reduced caloric 
intake and increased energy expenditure in the Siberian hamster. PET-CT studies 
demonstrated that FGF21 increased the uptake of glucose in BAT and WAT independently of 
reduced food intake and body weight as demonstrated by imaging of the pair-fed group. 
Furthermore, FGF21 increased glucose uptake in primary adipocytes, confirming these in vivo 
effects may be due to a direct action of FGF21 at the level of the adipocyte. Mechanistically, 
the effects of FGF21 are associated with activation of the ERK signalling pathway and 
upregulation of GLUT4 protein content in all fat depots. In response to treatment with FGF21, 
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we observed increase in markers of lipolysis and lipogenesis in both subcutaneous and 
visceral WAT depots. In contrast, FGF21 was only able to directly increase the uptake of lipid 
into BAT.  
Conclusions: These data identify brown and white fat depots as primary peripheral sites of 
action of FGF21 in promoting glucose uptake, but also indicate FGF21 selectively stimulates 
lipid uptake in brown fat, which may fuel thermogenesis. 
 
Key words: FGF21; β-klotho; white adipose tissue; brown adipose tissue; glucose uptake; lipid 
uptake.  
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1.0 Introduction 
Fibroblast growth factor 21 (FGF21) is a member of the FGF superfamily, which regulates 
metabolic homeostasis and is a potential therapeutic target for the treatment of metabolic 
syndrome [1]. Pharmacological administration of FGF21 to obese and diabetic animal models 
results in multiple metabolic benefits including improved glucose homeostasis via increased 
insulin sensitivity and reduced body weight [2-4]. FGF21’s pleiotropic effects are determined 
by expression of the FGFR1 and an obligate co-receptor, β-klotho (KLB) [5]. However, FGF21 
can also activate FGFR3c and KLB [6]. The restricted expression of KLB in adipose tissue (AT) 
and specific regions of the brain dictate the tissue specific actions of FGF21. Multiple studies 
have implicated the importance of AT and the central nervous system (CNS) for FGF21 
biology. Deletion of the receptor isotype FGFR1 or KLB from AT impairs the insulin sensitizing 
effects of FGF21, and the effects of antibodies targeting the FGFR1 are impaired in 
lipodystrophic mice [7-10]. It was recently shown in mice genetically engineered to delete KLB 
signalling from white AT (WAT) that AT is required for the acute insulin-sensitizing effects of 
FGF21 [11]. Previously continuous intracerebroventricular (ICV) infusion of FGF21 was shown 
to increase food intake and energy expenditure in diet-induced obese rats, whilst mice lacking 
KLB in the suprachiasmatic nucleus (SCN) and hindbrain are refractory to the effects of FGF21 
[12; 13]. Furthermore, infusion of FGF21 into the lateral ventricle in mice was shown to 
stimulate browning of AT, which raises the possibility that some of the effects of FGF21 on AT 
are centrally-mediated [14]. 
We have previously studied the biology of FGF21 action in the Siberian hamster, a natural 
model of adiposity that increases body weight as it accumulates AT in long day summer 
photoperiods (LD) but catabolizes these depots to support winter survival in short 
photoperiods (SD) [15].  Hamsters in the LD state offer the possibility of studying the actions 
of FGF21 in fat animals without the confounding effects of the development of insulin 
resistance. We have previously shown that FGF21 treatment suppresses appetite and 
promotes lipid oxidation in the LD state, but these effects are lost in the winter SD state, which 
is associated with reduced adiposity [16]. Although the mechanisms underlying the reduced 
responsiveness to FGF21 in the SD state are not yet known, we have also demonstrated that 
the effects of FGF21 are attenuated in aged Siberian hamsters, which also display reduced 
adiposity [17], reinforcing the importance of AT in mediating the metabolic effects of FGF21. 
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In humans with type 2 diabetes (T2D), chronic administration of FGF21 analogues lowers body 
weight and improves plasma lipid profiles [18; 19]. However, which specific adipose tissue 
depots may account for the metabolic effects of FGF21 and the underlying mechanisms via 
which these are achieved have yet to be fully elucidated [20].   
In the present study, we sought to determine the relative importance of different depots of 
AT [interscapular brown (iBAT), interscapular subcutaneous white (sWAT) and peri-renal 
(visceral) white AT (vWAT)] in governing FGF21-mediated metabolic improvements using a 
combination of in vivo studies utilising quantitative PET-CT imaging with both glucose and 
lipid tracers to assess the location and magnitude of their uptake, with ex vivo, metabolic and 
molecular biology approaches. By combining whole-body physiology along with mechanistic 
studies, we demonstrate the adipose tissue specific capacity for glucose and lipid uptake and 
metabolism and the importance of adiposity, and in particular KLB expression, in governing 
FGF21 responsiveness.  
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2.0 Methods 
2.1 Animals 
Adult male Siberian hamsters were obtained from a colony maintained at the University of 
Nottingham Biomedical Services Unit. All studies were approved by the University of 
Nottingham Local Ethical Review Committee and carried out in accordance with the UK 
Animals (Scientific Procedures) Act of 1986 (project license: PPL 40/3604 and PFBB5B31F). 
Siberian hamsters were housed as previously described [21]. Pair-fed (PF) hamsters were food 
restricted (twice, daily) to the average intake of FGF21 treated animals (off-set by 48h) as 
previously described [22]. 
 
2.2 Chronic FGF21 (LY2405319) treatment 
Prior to surgery, animals were singly housed to accurately determine food intake. Age-
matched animals in the LD (16hr light, 8hr dark) and SD (16hr dark, 8hr light, lights off at 
11:00) condition received a subcutaneously implanted Alzet osmotic mini-pump (Model 
1007D, Charles River) releasing vehicle (saline) or FGF21 (LY2405319; 3mg/kg/day) for 7 days 
as previously described [17]. This infusion paradigm would be expected to increase circulating 
FGF21 concentrations by at least 2.5-fold over the course of the study. Food intake and body 
weight were measured daily. Three days post-surgery, animals were transferred to metabolic 
cages (Columbus, Linton Instrumentation, UK). 
 
2.3 Metabolic cages 
Oxygen consumption and carbon dioxide production [used to calculate the respiratory 
exchange ratio (RER) and energy expenditure (EE)] were measured concurrently in a modified 
open-circuit calorimeter known as the comprehensive laboratory animal monitoring system 
(CLAMS) as previously described [21].  
 
2.4 Assessment of body composition and whole-body glucose and lipid uptake 
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Six days post-surgery animals morphologic and molecular imaging was undertaken using a 
nano-positron emission tomography-computed tomography (nanoPET-CT) imaging scanner  
(Mediso Medical Imaging Systems, Budapest, Hungary) to quantify body composition, tissue-
specific glucose and lipid uptake using 18F-fluorodeoxyglucose (18F-FDG) (10 MBq per animal) 
and 18F-4-thiapalmitate (18F-PAL) (8MBq per animal), respectively, as previously described 
[23; 24]. The magnitude of tissue-specific 18F-FDG and 18F-PAL uptake was expressed as the 
standard uptake value (SUV) defined as the average 18F activity in each region of interest (in 
kBq/cm3) divided by the injected dose (kBq) and multiplied by the body weight of each animal 
(kg). 
  
2.5 Primary adipocytes 
All reagents were obtained from Sigma, unless otherwise stated. 8-12 weeks old male LD 
Siberian hamsters were used to obtain primary adipocytes. Briefly, the fat pads (iBAT, sWAT 
and vWAT) were removed, chopped and digested using collagenase D and dispase II at 37oC 
with constant agitation for 1hr in PBS containing 10mM CaCl2. The digestion was stopped by 
adding DMEM/F12, centrifuging at 900 x g for 10min and resuspension of pellet in RBS Lysis 
Buffer Solution, centrifuging at 900 x g for 10min, and resuspension in DMEM/F12 containing 
10% FBS and pen/strep. The media was changed every 2 days until 95% confluent. To 
differentiate BAT cultures, cells were treated with 5µg/ml insulin, 1nM T3, 125µM 
indomethacin, 2µg/ml dexamethasone, 500µM IBMX and 0.5µM Rosi for 48hr. WAT cultures 
were treated with 5µg/ml insulin, 2µg/ml dexamethasone and 500µM IBMX only for 48h. On 
day 2, BAT cultures were treated with 5µg/ml insulin, 1nM T3 and 0.5µM Rosi, whilst WAT 
cultures were treated with 2µg/ml dexamethasone only. On days 4, 6, 8 and 10, cells were 
maintained in DMEM/F12, 10% FBS and pen/step before treatment with 100nM LY2405319 
for 48h. Non-insulin stimulated glucose uptake (normalised for protein content) was 
determined using [3H]2-deoxyglucose as previously described [25]. 
 
2.6 Molecular and biochemical analysis 
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Animals were subsequently euthanised via an intraperitoneal injection of sodium 
pentobarbitone (Euthatal, Rhone Merireux, Harlow, UK) and samples of the brain, liver, iBAT, 
sWAT and vWAT were collected and snap frozen on dry ice and stored at -80oC until required. 
Total RNA, protein (see Supplementary Table 1 for antibody information, and Supplementary 
Figure 4 for examples of Western blots) and TAG were extracted and analysed as previously 
described [23; 26]. Glycerol-3-phosphate was determined as per the manufacturer’s 
instructions (Sigma MAK207, UK). Pyruvate dehydrogenase complex (PDC) activity was 
determined as previously described [27].  
 
2.7 Statistical analysis 
Descriptive statistics (means ± SEM) were generated using GraphPad Prism (Prism 7.0, 
GraphPad, San Diego, USA). Data were analysed using two-way ANOVA, one-way ANOVA or 
Student’s T-test as appropriate. No animals were excluded from the analyses. Statistical 
significance was accepted at p < 0.05.   
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3.0 Results 
Effects of FGF21 on body weight, activity, substrate oxidation rates and tissue thermogenic 
markers (Figure 1) 
 Chronic treatment with FGF21 significantly reduced body weight and fat mass in Siberian 
hamsters maintained in the LD fat state (Figure 1A). Body weight loss was associated with a 
lowered daily caloric intake and increased energy expenditure (Figure 1B and C). Hamsters 
maintained in LD but pair-fed (PF) to match the intake of hamsters undergoing FGF21 
treatment also lost body weight; however, the magnitude of weight loss was attenuated 
when compared to ab libitum fed FGF21-treated animals (PF = 12.8 vs FGF21 = 18.1%, p < 
0.05, Figure 1B). Treatment with FGF21 reduced RER in hamsters maintained in LD, indicating 
an increase in whole-body lipid oxidation (Figure 1C). This was a consequence of FGF21 
treatment per se, as the PF animals maintained higher RER values that were similar to the ad 
lib fed vehicle control group (Figure 1C). Interestingly, PF animals also demonstrated 
increased EE, however, this was limited to the dark phase (Figure 1D) and appeared to be a 
consequence of increased ambulatory activity (Figure 1E). The ambulatory activity of FGF21-
treated animals and vehicle-treated controls was comparable (Figure 1E). The whole-body 
increase in energy expenditure was associated with a significant increase in UCP1 and DIO2 
mRNA expression in iBAT, sWAT and vWAT in FGF21 treated animals (Figure 1F-H). In the PF 
group, these thermogenic markers were significantly reduced as compared to vehicle-treated 
control animals (Figure 1F-H).  
Effects of FGF21 on tissue glucose uptake (Figure 1 and Supplemental Figure 1A) 
 We assessed tissue-and depot-specific glucose uptake in response to treatment with FGF21 
in vivo using nanoPET-CT and 18F-FDG. Treatment with FGF21 increased glucose uptake in 
iBAT, sWAT and vWAT compared to vehicle-treated controls (Figure 1I and J). The increase in 
sWAT and vWAT depots was similar. This was a direct effect of treatment, rather than a 
consequence of reduced food intake, as glucose uptake in the PF group was similar to an ad 
lib fed control group (Figure 1I and J). Glucose uptake in response to treatment was 
unaffected in other tissues including brain, liver, muscle and testes (Supplemental Figure 1A). 
To investigate whether the AT response was a direct effect of FGF21 treatment at the level of 
the adipocyte, we treated hamster primary adipocytes differentiated from stromal avascular 
 
 
11 
cells isolated from iBAT, sWAT and vWAT with a pharmacological dose of FGF21 (100 nM for 
48h). FGF21 increased glucose uptake significantly in cultures from both tissues and depots 
(Figure 1K). In line with the whole-tissue findings, treatment with FGF21 also induced a 10- 
and 3-fold increase in UCP1 mRNA in iBAT and WAT cultures respectively (p < 0.01).  
Effects of FGF21 on tissue signalling proteins, transporters and enzymes (Figure 2, 
Supplemental Figure 3) 
Tissue-specific phosphorylation events downstream of the FGFR1c-KLB receptor complex, 
namely pERK1/2, were significantly increased in the iBAT, sWAT and vWAT of FGF21-treated 
animals (Figure 2A, B and C). Treatment with FGF21 also increased GLUT1 protein content (a 
downstream target of ERK1/2) in iBAT (Figure 2D). This increase was not apparent in either 
WAT depot (Figure 2E and F). However, GLUT4 protein (also a target of ERK1/2) was 
significantly increased in iBAT and both WAT depots (Figure 2G-I). There were no changes in 
either GLUT1 or GLUT4 protein abundance in response to PF in either tissue. ERK 
phosphorylation also contributes to AT lipolysis [28; 29]. In the present study, key markers of 
lipolytic capacity, namely ATGL and pHSL660, were unaffected by treatment in iBAT (Figure 2J 
and M), however, the PF group showed a significant reduction in both markers.  In contrast, 
treatment with FGF21 increased ATGL content and pHSL660 in sWAT and vWAT (Figure 2K and 
L, 2N and O respectively). These responses do not appear to be a consequence of reduced 
food intake as there were no significant changes in those lipolytic proteins in the PF group 
when compared to control (saline) group. The phosphorylation of ACC (pACC), a key enzyme 
in tissue lipogenesis that controls the conversion of acetyl-CoA to malonyl-CoA, was 
unaffected in iBAT by FGF21 treatment or reduced food intake in PF (Figure 2P). On the other 
hand, pACC was reduced in WAT, and therefore its activity increased, in response to FGF21 
treatment (Figure 2Q-R), with a more pronounced effect observed in sWAT when compared 
to vWAT. We then assessed the activation of PDC, which controls the conversion of pyruvate 
to acetyl-CoA that is the substrate for ACC. Both FGF21 treated and PF animals demonstrate 
increases (0.49 ± 0.10 and 0.33 ± 0.07 nmol acetyl CoA/mg/min, p < 0.05, respectively) in PDC 
activity in vWAT when compared to the control (saline) group (0.07 ± 0.01 nmol acetyl 
CoA/mg/min). In BAT, there was a tendency (P=0.09) for an increase in PDC activity in the 
FGF21 (1.48 ± 0.45 nmol acetyl CoA/mg/min) but not PF group (0.70 ± 0.32 nmol acetyl 
CoA/mg/min) when compared with saline (0.56 ± 0.10 nmol acetyl CoA/mg/min). 
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Effects of FGF21 on tissue metabolites (Figure 3) 
Treatment with FGF21 reduced TAG content in iBAT and both WAT depots (Figure 3A). Cold-
activated BAT uses large amounts of TAG for thermogenic purposes, therefore there is a 
biological need for efficient mechanism(s) ensuring the continuous replenishment of 
intracellular lipid stores. This includes glucose uptake that is used for de novo lipogenesis and 
glycerol synthesis [30]. This study measured the levels of glycerol-3-phosphate (G3P), a key 
intermediate in lipogenesis that is required for the re-esterification of TAG. In line with 
increased glucose uptake and ACC activity, treatment with FGF21 resulted in a significant 
increase in G3P concentration in sWAT and vWAT, but not iBAT (Figure 3B). In the PF control 
group, levels of G3P were comparable to saline-treated animals.  
Effects of FGF21 on tissue lipid uptake and associated proteins (Figure 3 and Supplemental 
Figure 1B) 
Since both glucose and fatty acids are important substrates for the replenishment of 
intracellular lipid stores in adipose tissue, we sought to ascertain the impact of FGF21 on 
tissue-specific lipid uptake in vivo. Utilising nanoPET-CT and infusion of 18F-PAL, we 
demonstrated that treatment with FGF21 significantly increased lipid uptake in BAT from 
hamsters held in LD (Figure 3C). This was a direct effect of treatment, rather than a 
consequence of reduced food intake as demonstrated by the absence of lipid uptake in BAT 
in the PF group. There was no effect of FGF21 treatment in WAT, however, the PF group 
demonstrated reduced lipid uptake in that tissue. Furthermore, lipid uptake in response to 
FGF21 treatment was unaffected in other tissues including brain, liver, quadriceps muscle and 
testes (Supplemental Figure 1B). The selective increase in lipid uptake in BAT in response to 
FGF21 treatment was not associated with altered mRNA expression of key proteins implicated 
in lipid transport into that tissue, namely LPL, CD36 and FATP1 (Figure 3E-G) previously 
implicated in lipid disposal in BAT and WAT [31]. However, there was an increase in the 
protein content of PPARa, a transcriptional regulator of FGF21, in the PF group when 
compared with control animals (Figure 3H). 
Importance of adiposity and KLB expression in governing FGF21 responsiveness (Figure 4 
and Supplemental Figure 2) 
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Having described the distinct roles of different AT depots in mediating the thermogenic and 
metabolic effects of FGF21 in Siberian hamsters maintained in LD fat state, we next sought to 
determine the importance of the state of adiposity on these effects using advantage of our 
preclinical natural model of adiposity. We showed transfer to SD for 12 weeks was associated 
with a reduction in body weight. In line with our previous studies, the effects of treatment 
with FGF21 were lost in this SD group at the nadir of their body weight cycle: food intake, 
body weight, RER, energy expenditure, UCP1 and DIO2 gene expression in AT, and tissue 
glucose uptake were all unaffected by FGF21 treatment (Supplemental Figure 2).  
We subsequently explored the mechanism behind this FGF21-resistant state in SD animals 
and the importance of tissue glucose uptake in the increase in whole-body EE. We took a 
second group of Siberian hamsters and exposed them to SD for 8 weeks – at this point, body 
weight was significantly reduced (Figure 4A) compared to that during LD, but animals were 
not at the nadir of the seasonal body weight cycle observed after 12 weeks exposure to SD. 
At this stage of the seasonal cycle, treatment with FGF21 still significantly reduced food intake 
and body weight (Figure 4B and C). Furthermore, RER was significantly reduced (Figure 4D) 
indicating an increase in whole-body lipid oxidation. However, the effects of FGF21 on whole 
body energy expenditure previously observed in LD were lost (Figure 4E). As with the 
hamsters studied in LD, there was no effect of FGF21 treatment on ambulatory activity (Figure 
4F). In addition, UCP1 and DIO2 expression in BAT and WAT was unaffected by treatment 
(Figure 4G-I). FGF21 treatment increased glucose uptake in sWAT and vWAT but not iBAT in 
this cohort (Figure 4J). This suggests the changes in glucose uptake in WAT are independent 
of changes in EE in this tissue, and instead the FGF21-induced increase in EE in the LD animals 
is likely associated with the increased thermogenesis in BAT. In the absence of treatment with 
FGF21, KLB levels in WAT in the hamsters exposed to SD for 8 weeks were comparable to LD 
animals; whilst at the nadir of body weight (12 weeks post-exposure to SD), KLB was 
significantly reduced in iBAT, sWAT and vWAT (Figure 4K). KLB was also reduced in the PF and 
FGF21 groups (Figure 4K); in the latter group the weight loss was similar to the SD group (PF 
= -12.8%, FGF21 = -18.1%, SD +8 = -9.8% and SD +12 wk group = -21.0%). This was associated 
with reduced pERK1/2 (Figure 4L).   
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4.0 Discussion 
In the present study we provide novel insight into whole-body and adipose tissue-specific 
depot mechanisms governing the metabolic effects of FGF21 in the Siberian hamster, a 
seasonal model of adiposity. The selective increase in glucose uptake in adipose tissue, which 
was a direct consequence of FGF21 treatment rather than a result of associated changes in 
food intake, energy expenditure and body weight, appears to be differentially regulated in 
WAT and BAT. In addition, we demonstrate lipid is exclusively taken up by BAT in response to 
treatment with FGF21 possibly to fuel thermogenesis either directly by being oxidised or 
indirectly by replenishing the TAG stores used for thermogenesis. This lipid is most likely 
supplied by WAT, as markers of lipolysis in both sWAT and vWAT are upregulated in response 
to FGF21 treatment. However, we also demonstrate increased markers of TAG synthesis and 
de novo lipogenesis in both WAT depots, but not BAT, as a result of treatment with FGF21. In 
the absence of lipid uptake in WAT, our data suggests the glucose uptake in this tissue may 
be used to supply both fatty acyl CoAs through the de novo lipogenesis pathway and the G3P 
required for the re-esterification of the glycerol backbone to TAG to provide further lipid 
stores for subsequent utilisation. In hamsters in LD, increased EE following treatment with 
FGF21 is associated with an increased glucose uptake in BAT, but both effects are lost in SD. 
Finally, we demonstrate that at the nadir of the bodyweight cycle there is a reduction in the 
expression of KLB associated with the loss of ERK1/2 phosphorylation in AT, altering its 
responsiveness to FGF21. Interestingly, KLB is significantly reduced in the PF group, suggesting 
weight loss per se alters expression of this obligate co-receptor for FGF21.  
FGF21 was previously shown to be a potent regulator of glucose uptake in 3T3-L1 adipocytes 
via GLUT1 [32]. Furthermore, FGF21 acts as an insulin sensitizer in mice to overcome 
peripheral insulin resistance induced by fasting in mice – an effect that is decreased in BAT of 
liver-specific FGF21 KO mice [4]. The findings from the present study extend those 
observations by combining mechanistic in vitro studies with an in vivo model of seasonal 
adiposity using PET-CT measurements to simultaneously assess in real-time both glucose and 
lipid uptake responses to FGF21 treatment in multiple tissues and different depots of AT. In 
the LD state, treatment with FGF21 significantly increases glucose uptake in BAT and both 
depots of WAT, which is a direct effect of treatment as demonstrated by the responses of the 
PF group and data from the primary adipocyte cultures. The mechanism by which glucose is 
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taken up and its fate, however, are differentially regulated. In BAT, we observed increases in 
GLUT1 and GLUT4 protein content suggesting insulin-independent and insulin-dependent 
mechanisms respectively. FGF21-induced GLUT1 expression in adipocytes is mediated by the 
Elk-1/SRF signalling cascade and is blunted in diet-induced obese mice [33]. Whilst in sWAT 
and vWAT, the increase in glucose uptake is mediated by GLUT4 only. Over-expression of 
FGF21 has been previously shown to increase GLUT4 mRNA expression in adipose tissue [34]. 
In the present study we extend that observation by showing an increase in the protein content 
of GLUT4 in both subcutaneous and visceral WAT depots as well as BAT [35]. It should be 
noted that BAT depots in rodents and humans are highly insulin sensitive. Indeed, insulin 
administration enhances glucose uptake in BAT in response to FGF21 treatment [36]. In the 
present study, the magnitude of the effect of FG21 on glucose uptake in BAT was 2-fold higher 
than WAT, which may be explained by the observation that GLUT4 is expressed at lower levels 
in WAT and our data in the Siberian hamster supports this [37]. Furthermore, this may explain 
why humans, which possess relatively less BAT, demonstrate less profound glucose lowering 
in response to FGF21 treatment when compared to rodents [18; 19]. However, human BAT 
has been shown to efficiently utilise fatty acids in vivo, and glucose uptake in BAT is not 
impaired in overweight subjects with T2D [38; 39]. Consistent with the FGF21-stimulated lipid 
uptake in BAT in the present study, the blood lipid profile is improved in humans treated with 
FGF21 analogues [18; 19]. Further clinical work is required to determine the contribution of 
BAT in pre-clinical models and human subjects (reviewed in [40]).  
The increase in glucose uptake in WAT appears to contribute to the regeneration of TAG. 
Indeed, treatment with FGF21 was shown to activate ERK phosphorylation in that tissue and 
this was associated with increased content/activity of key markers of lipolysis (ATGL and 
pHSL), de novo lipogenesis (ACC) and glycerol synthesis (G3P). The increase in PDC activity in 
WAT, which controls the conversion of pyruvate to acetyl-CoA, the substrate for ACC, further 
supports this notion. In contrast, the absence of effects of FGF21 on pACC and G3P in BAT, 
along with the tendency for an increase in PDC activity, suggests that most glucose taken up 
is oxidised in that tissue and hence, unlike WAT, de novo lipogenesis and glycerol synthesis 
do not substantially contribute to replenishment of intracellular lipid stores under those 
conditions.  
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We also demonstrate that treatment with FGF21 increases lipid uptake in BAT alone; we 
suggest the primary purpose of the lipid taken up is to both replenish the intracellular TAG 
stores in this tissue and fuel the increase in EE through thermogenesis. FGF21 may promote 
fatty acid uptake in adipocytes directly or indirectly via insulin sensitization; uptake was 
previously shown to be mediated via fatty acid transporters such as CD36 or FATP1 in 
adipocytes [31; 41]. Although the findings from the present study indicate that the FGF21-
induced uptake of lipid in BAT was not mediated by upregulation in the protein content of 
CD36, FATP1 or LPL, the possibility that changes in their intrinsic activity may play a role 
cannot be ruled out. The selective utilisation of plasma-derived lipids in BAT, without further 
significant storage in WAT, may contribute not only to lipid lowering effects previously 
reported but also to the weight loss and insulin sensitisation effects of FGF21 [31]. In addition, 
the increase in EE following treatment with FGF21 in LD animals is associated with an increase 
in glucose and lipid uptake in BAT, although this effect is lost in SD animals. In contrast, 
glucose uptake in WAT in response to treatment with FGF21 is still evident in the SD state 
prior to body weight reaching a nadir. This suggests the FGF21-induced increase in glucose 
uptake in WAT is independent of whole-body changes in EE. This is in contrast to previous 
suggestions that the increase in thermogenic markers in WAT may stimulate glucose uptake 
via upregulation of GLUT4 [35]. 
We previously highlighted the importance of adiposity per se in governing FGF21 
responsiveness and demonstrated that Siberian hamsters at the nadir of their body weight 
cycle following exposure to SD become completely unresponsive to exogenous FGF21 [16; 
17]. Here we extend those findings and demonstrate that at the nadir of the body weight 
cycle, KLB in all adipose tissue depots is reduced, and this is associated with a loss of ERK1/2 
phosphorylation in response to treatment with FGF21. However, before body weight reaches 
a nadir, animals remain FGF21 responsive. As SD exposure enhances sympathetic nervous 
system drive, increases UCP1 expression in BAT and WAT and induces lipolysis, it may be 
FGF21 is unable to further drive this already maximal lipolytic and catabolic state at the nadir 
of the body weight cycle [42; 43].   
Our data do not exclude a role for FGF21 in the CNS. Previously, infusion of FGF21 into the 
lateral ventricle of mice was shown to stimulate the browning of AT, an effect that was 
attenuated in mice treated with a generic β-blocker, and lost in mice lacking β-
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adrenoreceptors [14]. Further work is required to delineate the role of FGF21 in the brain of 
the current seasonal model of adiposity. Recently a role for hypothalamic tanycytes in 
mediating the actions of FGF21 has been proposed. Indeed, we previously demonstrated a 
role for FGFR1c in tanycytes contributing to regulation of food intake, an effect probably 
mediated by tanycytes regulating the local availability of thyroid hormone in the surrounding 
hypothalamus [26]. In contrast to mice, that demonstrate increased food intake in response 
to treatment with FGF21, appetite in hamsters is consistently suppressed by FGF21 [3; 16; 
17]. The FGF21-induced increase in appetite in mice is probably a compensatory response to 
enhanced whole-body energy expenditure, and therefore the defence of body weight or 
further metabolic fuel to drive thermogenesis. A suppressive action of FGF21 on appetite in 
hamsters is consistent with their known biology, in that a change in ingestive behaviour is a 
major driver of their seasonal cycle of adiposity. Exposure of Siberian hamsters to SD for a 
period of weeks induces a profound (~25%) chronic decrease in voluntary food intake, so 
hypophagia is a natural state in this species. In addition, this natural SD-induced hypophagia 
is associated with increased hepatic and brown fat production of FGF21 [45].  
Correspondingly, peripheral treatment of Siberian hamsters with FGF21 results in 
upregulation of Dio2 in the hypothalamus; this enzyme converts thyroid hormone into its 
biologically active form [17]. Altered local concentration of thyroid hormone is considered the 
main hypothalamic driver of the seasonal cycle of appetite and energy expenditure in this 
species, therefore it is a likely central pathway of action for FGF21 [46; 47].  
Conclusions. Taken together, our studies reveal novel insights into the primary sites and 
mechanisms of action of FGF21 using a preclinical natural model of adiposity, the Siberian 
hamster. They also highlight the importance of adipose tissue and KLB expression in governing 
the metabolic and homeostatic actions of FGF21, which produce differential effects in WAT 
and BAT, though we did not detect differences in the responses of subcutaneous and visceral 
WAT to FGF21. Our data indicate that glucose uptake in WAT may be used for de novo 
lipogenesis and TAG synthesis, whereas the selective increase in lipid uptake in BAT may fuel 
thermogenesis.  These findings have important implications for FGF21’s therapeutic potential 
in metabolic diseases that improve the understanding of this hormone and how it can be 
further exploited in future studies.  
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Figure legends 
Figure 1. FGF21 reduces body weight via reduced food intake and increased energy 
expenditure in Siberian hamsters in long days (LD). (A) Food intake, (B) Body weight, (C) RER, 
(D) energy expenditure, (E) ambulatory activity, (F, G and H) UCP1 and DIO2 mRNA expression 
in AT, (I and J) glucose uptake of Siberian hamsters treated with FGF21, vehicle or pair-fed to 
match food intake of FGF21-treated group. Data are mean ± SEM. N=4/group. *p < 0.05, ***p 
<0.001. (K) Glucose uptake of primary adipocytes derived from interscapular brown adipose 
(iBAT), interscapular subcutaneous white adipose (sWAT) or visceral (perirenal) white adipose 
(vWAT) treated with FGF21. N=8 per treatment. Data presented as mean ± SEM. *p < 0.05 vs 
vehicle control. 
 
Figure 2. FGF21-stimulated glucose uptake in adipose tissue relates to GLUT1 and GLUT4 
protein expression in vivo. (A-C) pERK1/2 activation, (D-F) GLUT1 expression, (G-I) GLUT4 
expression, (J-L) ATGL expression, (M-O) pHSL660 and (P-R) pACC in iBAT, sWAT and vWAT in 
response to treatment with FGF21 in vivo. Data are mean ± SEM. N=4/group. Statistical 
analysis conducted using one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05, 
**p <0.01, ***p < 0.001, ****p < 0.0001.  
 
Figure 3. FGF21-stimulated lipid uptake in iBAT. (A) TAG and (B) G3P content of iBAT, sWAT 
and vWAT and (C) lipid uptake in iBAT, sWAT and vWAT in response to treatment with FGF21 
or vehicle or in pair fed controls (PF). Data are mean ± SEM. N=4/ group.  Statistical analysis 
conducted one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05. (E) LPL, (F) 
CD36, (G) FATP1, (H) PPARα expression in iBAT in response to treatment with FGF21 (vs saline 
controls). N=4/group. Data are mean ± SEM. N=4/group. Statistical analysis conducted by 
one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05. 
 
Figure 4. FGF21 reduces body weight via reduced food intake in Siberian hamster in short 
days (SD) before body weight reaches a seasonal nadir. (A) Body weight loss in response to 
exposure to SD. (B) Food intake, (C) Body weight, (D) RER, (E) energy expenditure, (F) 
ambulatory activity, (G-I) UCP1 and DIO2 mRNA expression in AT, (J) glucose uptake in 
Siberian hamsters treated with FGF21 or vehicle. Data are mean ± SEM. N=4/group. Statistical 
analysis conducted by two-way ANOVA, one-way ANOVA or Students T-test as appropriate. 
*p < 0.05, ***p <0.001, ****p < 0.0001. (K) KLB expression and (L) pERK1/2 in Siberian 
hamsters in LD, treated with FGF21, PF to treatment group, or exposed to SD (8 and 12 weeks 
respectively). a p < 0.05 vs LD, b p < 0.05 vs SD + 8 weeks or 12 weeks, respectively. 
 
Supplemental Figure 1. FGF21 does not induce glucose and lipid uptake beyond adipose 
tissue. (A) Glucose uptake of brain, liver, quadriceps muscle and testes of Siberian hamsters 
in LD treated with FGF21, vehicle or pair-fed to match the food intake of FGF21-treated group. 
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Data are mean ± SEM. N=4/group. Statistical analysis conducted one-way ANOVA. (B) Lipid 
uptake of brain, liver, quadriceps muscle and testes of LD Siberian hamsters treated with 
FGF21, vehicle or pair-fed to match the food intake of FGF21-treated group. Data are mean ± 
SEM. N=4/group. Statistical analyses conducted by one-way ANOVA.  
 
Supplemental Figure 2. Siberian hamsters at the nadir of body weight after 12 weeks 
exposure to short days (SD) are unresponsive to FGF21. (A) Body weight loss, (B) Food intake, 
(C) Body weight, (D) RER, (E) energy expenditure, (F) ambulatory activity, (G-I) UCP1 and DIO2 
mRNA expression, (J) glucose uptake of Siberian hamsters treated with FGF21, vehicle or pair-
fed to match the food intake of FGF21-treated group.  Data are mean ± SEM. N=4/group.  
 
Supplemental Figure 3. Representative Western blots underlying protein abundance 
depicted in Figure 2. pERK1/2 activation (phosphorylation), total ERK, GLUT1, GLUT4 
expression, ATGL, pHSL660, pACC and control cyclophilin blots are depicted for interscapular 
brown fat (iBAT), subcutaneous white adipose tissue (sWAT) and visceral white adipose tissue 
(vWAT).  
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Supplemental Table 1. Antibodies. 
Peptide/protein target Name of Antibody 
Manufacturer, catalog 
#, and/or name of 
individual providing 
the antibody 
Species raised in; 
monoclonal or 
polyclonal 
Dilution 
used    RRID  
ATGL 
Anti-Adipose 
Triglyceride Lipase 
antibody 
[EPR3444(2)] 
(ab109251) 
Abcam, #ab109251 Rabbit monoclonal 1 in 1000 AB_10864772 
phospho-ACC 
Phospho-Acetyl-CoA 
Carboxylase (Ser79) 
Antibody #3661 
Cell Signalling, #3661 Rabbit polyclonal 1 in 1000 AB_330337 
Cyclophilin B (PPIB) 
Anti-Cyclophilin B 
antibody [k2E2] 
(ab74173) 
Abcam, #ab74173 Mouse monoclonal 1 in 4000 AB_1268387 
GLUT1 
Anti-Glucose 
Transporter GLUT1 
antibody (ab652) 
Abcam, #ab652 Rabbit polyclonal 1 in 2000 AB_305540 
GLUT4 
Anti-Glucose 
Transporter GLUT4 
antibody (ab33780) 
Abcam, #ab33780 Rabbit polyclonal 1 in 2000 AB_2191441 
phospho-HSL 
Phospho-HSL 
(Ser660) 
Antibody #4126 
Cell Signalling, #4126 Rabbit polyclonal 1 in 1000 AB_490997 
Actin 
Anti-Actin antibody 
produced in rabbit 
(A2066) 
Sigma, #A2066 Rabbit polyclonal 1 in 5000 AB_476693 
phospho-ERK1/ERK2 
Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
(D13.14.4E) XP® 
Rabbit mAb #4370 
Cell Signalling, #4370 Rabbit monoclonal 1 in 500 AB_2315112 
Total ERK1/ERK2 
p44/42 MAPK 
(Erk1/2) (3A7) 
Mouse mAb #9107 
Cell Signalling, #9107 Mouse monoclonal 1 in 1000 AB_10695739 
LPL 
Anti-Lipoprotein 
lipase antibody 
[LPL.A4] 
Abcam, #ab21356 Mouse monoclonal 1 in 1000 AB_446221 
CD36 CD36/SR-B3 Antibody Novus, #NB400-144 Rabbit polyclonal 1 in 5000 AB_10003498 
FATP1 Anti-SLC27A1 antibody 
Sigma, #SAB1402095-
100UG Rabbit polyclonal 1 in 1000 AB_10609989 
PPARa 
Anti-PPAR alpha 
antibody Abcam, #ab8934 Rabbit polyclonal 1 in 1000 AB_306869 
 
